AstraZeneca's Calquence receives EU approval for untreated MCL, offering new hope with improved survival rates. This report details clinical trial results and market implications.
AstraZeneca's 6-K reveals Breztri's successful Phase III asthma trial results, showing significant lung function improvements and a strong safety profile, paving the way for enhanced treatment options.
AstraZeneca PLC's recent Form 6-K reveals Non-Executive Director Karen Knudsen's purchase of 1,400 ADSs, reflecting confidence in the company's future. Key insights on compliance and market sentiment.
Explore AstraZeneca PLC's May 2025 Form 6-K report detailing 1.55B voting rights and regulatory compliance.
Discover AstraZeneca's financial report on Calquence's EU approval for untreated CLL, highlighting significant trial results and market potential.
AstraZeneca's SEC report reveals the discontinuation of the CAPItello-280 trial for mCRPC. Discover the reasons, trial details, and future strategies in prostate cancer treatment.
Explore AstraZeneca's Q1 2025 financial performance with a 10% revenue increase. Key insights highlight profitability growth and ongoing regulatory scrutiny. Investors advised to hold.
Discover the pivotal findings from AstraZeneca's DESTINY-Breast09 trial, showcasing Enhertu's potential in HER2-positive metastatic breast cancer and its impact on patient care.
Explore key insights from AstraZeneca's 2025 AGM, highlighting shareholder support, board changes, and future outlook. Discover why we recommend a 'Hold' amid market uncertainties.
Discover how AstraZeneca's Imfinzi, approved for resectable NSCLC, offers new hope with a 32% reduced recurrence risk, transforming patient care in Europe.
Discover the implications of Enhertu's EU approval for HER2-low breast cancer and its impact on AstraZeneca's financials, market potential, and future developments.
Explore AstraZeneca PLC's April 2025 financial report detailing voting rights, regulatory compliance, and company overview in the biopharmaceutical sector.